LUMAKRAS ® (sotorasib) Demonstrated Delayed Time to CNS Progression, Longer CNS PFS and Higher Intracranial ORR vs Docetaxel in Post-Hoc Analysis of Phase 3 CodeBreaK 200 Trial LUMAKRAS Shows Improved PFS vs Docetaxel Across Key Co-Alteration Subgroups in the Phase 3 CodeBreaK 200 Study LUMAKRAS Plus Vectibix® (panitumumab) and FOLFIRI Combination Show ORR of 55% in Previously Treated … Read more
Vorasidenib demonstrated an unprecedented improvement in progression free survival with a median of 27.7 months in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation; key secondary endpoint of time to next intervention significantly improved in the vorasidenib arm Results presented at the ASCO 2023 plenary session, highlighting significance for patients with … Read more
Nivolumab added to AVD chemotherapy expected to become new standard for initial treatment for advanced stage disease in adolescents and adults, based on trial data to be presented at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session LOS ANGELES and PORTLAND, Ore., June 4, 2023 /PRNewswire/ — A Phase 3 trial has … Read more
A strategic partnership between the Jordanian Ministry of Digital Economy and IrisGuard to implement iris recognition technologies for Government digital services delivery AMMAN, Jordan, June 4, 2023 /PRNewswire/ — Today, IrisGuard and the Jordanian Ministry of Digital Economy and Entrepreneurship signed a strategic partnership agreement for the use of iris recognition to enhance access to Governmental and … Read more
ROCKVILLE, Md. and SUZHOU, China, June 3, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, updated the Phase 1b efficacy and safety results of IBI939 (anti-TIGIT antibody) combined with sintilimab (anti-PD-1 … Read more
Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX FASPRO® combination biweekly regimen showed an overall response rate of more than 80 percent CHICAGO, June 3, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the pivotal Phase 1/2 MonumenTAL-1 study of the investigational … Read more
CHICAGO, June 3, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI® (teclistamab-cqyv), a first-in-class BCMAxCD3 bispecific antibody, and talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, showing a high overall response rate (ORR) among patients with relapsed or refractory multiple myeloma (RRMM).1 … Read more
Data on BCMA/CD19 dual-targeting FasTCAR-T GC012F showed 100% minimal residual disease (MRD) negativity and 82.8% MRD negative stringent complete response (sCR) in a predominantly high-risk relapsed/refractory multiple myeloma (RRMM) population Data on GC012F for treatment of B-NHL will be presented on June 5 in a poster presentation at 2023 ASCO Annual Meeting SAN DIEGO, Calif., … Read more
Une présentation orale intitulée « Phase 1/2 Study of DF1001, an Immune Modulating TriNKET® Targeting HER2, in Patients with Advanced Solid Tumors: Phase 1 DF1001 Monotherapy Dose Escalation Results » sera présentée par Howard Safran, directeur médical, lors de la session ASCO Developmental Therapeutics – Immunotherapy le 4 juin. WALTHAM, Mass., 3 juin 2023 /PRNewswire/ — Dragonfly Therapeutics, Inc, une société … Read more
BOYNTON BEACH, Fla, June 3, 2023 /PRNewswire/ — Sanctuary Cannabis, a trusted provider of high-quality medical cannabis products, is excited to announce the grand opening of its 19th medical cannabis dispensary in Boynton Beach, Florida. The new dispensary is located at 710 N Federal Hwy, Boynton Beach, FL 33435, United States. The grand opening event … Read more